Leerink team expects an announcement regarding breakthrough status
this was in yahoo news finance summary yesterday. GONE TODAY!
Insmed Inc. (INSM) provided a spring interim update from the CLEAR-110 study, an ongoing, two-year, open-label extension study of once-daily Arikace, or liposomal amikacin for inhalation, to treat Pseudomonas aeruginosa in cystic fibrosis patients. These data are from 98 patients who have completed the first 12 months of the CLEAR-110 extension study. The data were collected as part of a scheduled data safety monitoring board review of the CLEAR-110 extension study. The data showed that Arikace was well tolerated, and there was a sustained improvement from baseline level in forced expiratory volume in one second.
The Leerink team expects an announcement regarding breakthrough status for the drug with huge upside, espe
cially if no Phase 3 study is required. The consensus price target is a stunning $33.40. Insmed closed Tuesday at $13.